DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Plitidepsin is an investigational drug.
There have been 11 clinical trials for Plitidepsin. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2010.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Lymphoma. The leading clinical trial sponsors are PharmaMar, Institut Bergonié, and Ministry of Health, France.
There are two US patents protecting this investigational drug and thirty-six international patents.
Recent Clinical Trials for Plitidepsin
|Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide||PharmaMar||Phase 2|
|A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma||PharmaMar||Phase 2|
|Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma||PharmaMar||Phase 1|
Top disease conditions for Plitidepsin
Top clinical trial sponsors for Plitidepsin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Plitidepsin||Start Trial||Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them||Pharma Mar, S.A. (Madrid, ES)||Start Trial|
|Plitidepsin||Start Trial||Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them||Pharma Mar, S.A. (ES)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|